Nabriva Therapeutics (NASDAQ:NBRV) Now Covered by Analysts at

Analysts at assumed coverage on shares of Nabriva Therapeutics (NASDAQ:NBRVGet Rating) in a report issued on Monday. The firm set a “hold” rating on the biotechnology company’s stock.

Nabriva Therapeutics Stock Performance

Shares of Nabriva Therapeutics stock opened at $2.31 on Monday. The firm’s fifty day simple moving average is $4.63 and its 200-day simple moving average is $4.86. The stock has a market capitalization of $61.49 million, a price-to-earnings ratio of -0.12 and a beta of 1.73. Nabriva Therapeutics has a 12 month low of $2.04 and a 12 month high of $28.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.81 and a quick ratio of 2.01.

Hedge Funds Weigh In On Nabriva Therapeutics

A hedge fund recently raised its stake in Nabriva Therapeutics stock. Renaissance Technologies LLC increased its holdings in Nabriva Therapeutics plc (NASDAQ:NBRVGet Rating) by 102.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 795,938 shares of the biotechnology company’s stock after acquiring an additional 402,144 shares during the quarter. Renaissance Technologies LLC owned approximately 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent quarter. 0.53% of the stock is currently owned by institutional investors and hedge funds.

About Nabriva Therapeutics

(Get Rating)

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia.

Featured Articles

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with's FREE daily email newsletter.